Key Highlights

  • November 22, 2026 is the FDA target action date for Molbreevi in autoimmune pulmonary alveolar proteinosis, the binary event that frames the trading in Savara (NASDAQ:SVRA) as launch preparations continue.
  • 7.6% was the gain in Savara to about USD 5.01 on October 7, 2026, published market data show, though the stock is still down 11.3% year to date.
  • USD 173.0 million of cash and short-term investments at June 30, 2026, simple arithmetic on USD 41.8 million and USD 131.2 million, against USD 30.1 million of debt.
  • 21% of shares were sold short as of September 15, 2026, with 36.2 days to cover, stub-reported figures that show how crowded a bet on the approval decision has become.

The October 7 Rise and the Analyst Angle

Savara (NASDAQ:SVRA) rose about 7.6% to USD 5.01 on October 7, 2026, according to published market data, with some quote pages showing a gain near 8.0% around midday. Early reports tied the move to Citizens reiterating its rating on the Molbreevi launch outlook, which we could not verify. Published market data also cited a JPMorgan initiation at Overweight with a USD 12 target the same day, also unverified. Cullinan Therapeutics (NASDAQ:CGEM) fell 0.6%. Corvus Pharmaceuticals (NASDAQ:CRVS) fell 1.1%. Kura Oncology (NASDAQ:KURA) rose 3.0%, a median of negative 0.6%, so the move was company specific. Trading value of about USD 6.89 million was below the typical USD 9.74 million, and shares finished near the top of a USD 4.69 to USD 5.05 range, per the stub.

Molbreevi, the PDUFA Date and the Funding Mechanism

Molbreevi is an inhaled formulation of molgramostim, a biologic meant to treat autoimmune pulmonary alveolar proteinosis, a rare lung disease. The FDA accepted the Biologics license application with a target action date of November 22, 2026. The company has said UK and European decisions are expected between the fourth quarter of 2026 and the first quarter of 2027. Savara has no product revenue, so approval matters for funding: it expects access to up to USD 150 million of non-dilutive Capital through Debt and Royalty arrangements after approval. The company has also said it is building a commercial team, including rare disease specialists. A first half 2026 net loss of USD 77.5 million and operating cash burn of USD 62.8 million set the clock.

Risks, Peers and What to Watch

The decision is binary. A delay or a complete response letter would hit the shares and could force new equity, which would dilute holders. Savara (NASDAQ:SVRA) is a single product company with a 52-week range of USD 3.34 to USD 7.00, and it trades below its 20-day, 50-day and 200-day averages of USD 5.13, USD 5.34 and USD 5.50. The 14-day RSI was 45.8 and MACD sat below its signal line, per published figures, so momentum is not yet decisive. Phase 3 IMPALA-2 data presentations were reported as accepted for the ERS Congress, and any new data could move the shares in either direction. Investors should watch any FDA communication ahead of November 22, 2026, European and UK regulatory steps, and the third quarter report, expected in early November; that date is unconfirmed.

Where Things Stand

Savara (NASDAQ:SVRA) shares rose about 7.6% on October 7, 2026 as sentiment around the Molbreevi launch improved, but the verified catalyst is the pending FDA decision on November 22, 2026, not any single analyst note. The June 30 Balance Sheet implies about 1.4 years of funding at the first half burn rate, simple arithmetic, yet the company has no Revenue and a heavy short position. One session of buying does not alter that binary risk.